Tau Pipeline Enabling Program V (T-PEP)

Tau Pipeline Enabling Program V (T-PEP) is sponsored by Alzheimer's Association. T-PEP supports translational projects aimed at advancing potential therapies for tauopathies, including Alzheimer's disease, progressive supranuclear palsy (PSP), and frontotemporal dementia (FTD).

Tau Pipeline Enabling Program V (T-PEP) Tau Pipeline Enabling Program V (T-PEP) Tau Pipeline Enabling Program V (T-PEP) Tau Pipeline Enabling Program V (T-PEP) T-PEP supports translational projects aimed at advancing potential therapies for tauopathies, including Alzheimer's disease, progressive supranuclear palsy (PSP), and frontotemporal dementia (FTD).

The program focuses on development candidate selection, lead optimization, in vivo proof-of-concept, and IND-enabling studies for tau or tau-related mechanisms. Projects centered on compound or target discovery are not responsive. View program objectives, LOI instructions, timelines, eligibility requirements and more.

Apply for the T-PEP research grant by submitting your LOI through the ProposalCentral website. Registration is required. The Tau Pipeline Enabling Program (T-PEP) seeks to accelerate the discovery of potential new therapies for tauopathies.

This program intends to enrich the pipeline for therapy development by facilitating the translation of academia-derived ideas into practical application. In short, T-PEP bridges the gap between innovative but resource-constrained researchers and the larger pharmaceutical companies that are looking for drug candidates to be taken into human trials.

The overarching goal of T-PEP is to promote the advanced study of a wide range of novel targets, agents, and/or therapeutic strategies that will accelerate the development of disease-modifying interventions for tauopathies. Academic institutions, nonprofit organizations, and small for-profit companies may apply. Preference is given to companies with 50 or fewer employees.

The principal investigator must be considered a full-time employee of the applicant organization. Postdoctoral applicants are not eligible to serve as PI but may be included as key personnel. Applicants must provide documentation confirming nonprofit or for-profit status.

All deadlines are 5 p. m. ET.

Late submissions will not be accepted. Letter of Intent launch: April 13, 2026 Letter of Intent deadline: May 28, 2026 Full application deadline: Aug. 14, 2026 Application review: Sept.

/Oct. 2026 Award notifications: Nov. 30, 2026 Project duration: Up to 2 years Nonprofits may request up to 10% indirect costs.

Indirect costs are not allowed for for-profit entities. Funds must support candidate development activities and milestone-driven translational work. A Letter of Intent is required and must be submitted through ProposalCentral.

Only applicants invited after LOI review may submit a full application. Full applications must be submitted online through ProposalCentral and include program-specific materials described in the RFA. Application review process LOIs and full applications are reviewed for program alignment, scientific rationale, methodological rigor, translational path, milestones, and potential impact on tauopathies.

Applicants should review the full RFA for detailed eligibility, application requirements, budget guidance, milestone expectations, and required attachments. All applicants and institutions are strongly encouraged to review the Conditions of Award before submitting an LOI. Alzheimer’s Association will serve as the funding body on behalf of the funding partners.

Grants made are generally open to scientists and researchers across the globe through their institution and/or organization; however, as a U.S.-based charity, the Alzheimer’s Association is subject to, and complies with, U.S. law. As a result, the Alzheimer’s Association cannot award, and will not award, grants in violation of applicable U.S. statutes and regulations.

This means, among other things, that the Alzheimer’s Association cannot, and will not, fund any individual or entity (i) that is subject to U.S. comprehensive or targeted sanctions or if awarding funding would result in a violation of such sanctions, (ii) that is on the U.S. List of Specially Designated Nationals or entities owned or controlled by such persons, or (iii) when doing so is otherwise prohibited by U.S. laws related to combating terrorism.

Please contact grantsapp@alz. org with any questions. Keep Up With Alzheimer's News and Events Yes, I would like to receive email from the Alzheimer's Association.

* hidden field used for source value to collect web page domain hidden field used for subsource value to collect web page url